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Abstract
Poly I:C is a powerful immune adjuvant as a result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 is a
nanoplexed formulation of Poly I:C complexed with polyethylenimine that causes tumor cell apoptosis showing
immunogenic cell death features and which upon intratumoral release results in more prominent tumor infiltration
by T lymphocytes. Intratumoral treatment with BO-112 of subcutaneous tumors derived from MC38, 4 T1 and B16-
F10 leads to remarkable local disease control dependent on type-1 interferon and gamma-interferon. Some degree
of control of non-injected tumor lesions following BO-112 intratumoral treatment was found in mice bearing bilateral
B16-OVA melanomas, an activity which was enhanced with co-treatment with systemic anti-CD137 and anti-PD-L1
mAbs. More abundant CD8+ T lymphocytes were found in B16-OVA tumor-draining lymph nodes and in the tumor
microenvironment following intratumoral BO-112 treatment, with enhanced numbers of tumor antigen-specific
cytotoxic T lymphocytes. Genome-wide transcriptome analyses of injected tumor lesions were consistent with a
marked upregulation of the type-I interferon pathway. Inspired by these data, intratumorally delivered BO-112 is
being tested in cancer patients (NCT02828098).
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Background
Intratumoral local immunotherapy is gaining interest as
a way to broaden the therapeutic window of immunother-
apy agents and confine their effects to the tumor micro-
environment and tumor-draining lymph nodes (TDLN) [1].
Moreover, a number of examples indicate that following
intratumoral release, therapeutic effects against distant
disease are observed beyond the injected tumor [1–3]. Im-
munotherapy agents in the form of cytokines [4, 5], recom-
binant viruses [6, 7], monoclonal antibodies (mAbs) [8],
and pathogen-associated molecular patterns [9–11] can be
delivered by intratumoral approaches.
Poly I:C is an analogue of double-stranded viral RNA
that acts as an agonist of innate immune receptors
deployed to detect infection by such microorganisms.
Endosomal TLR3 and intracellular MDA5 and RIG-I
may detect the compound leading to upregulation of
type-I interferon (IFN-I) and other proinflammatory
pathways [12, 13]. Indeed, Poly I:C was originally de-
scribed for its effects as an exogenous IFNα/β inducer
[14] with well documented antiviral and antitumor
effects in mice [15, 16]. These include immunotherapeu-
tic efficacy observed following intratumoral injections
[16–18] and it has been extensively used as a vaccine
adjuvant including cancer vaccines [19–22].
A number of compounds have been produced to ex-
ploit the proimmune effects of Poly I:C in the clinic.
Among these are Ampligene [23], Hiltonol [24–26] and
BO-112 [27]. Hiltonol, a Poly I:C formulation stabilized
by poly-L-lysine, is the most advanced of such com-
pounds in the clinic, as it has been tested subcutane-
ously in healthy volunteers [28] and in cancer patients
when given intratumorally [10, 29] and intramuscularly
[30]. In healthy volunteers, subcutaneous injection induces
prominent transient inflammation and a marked type-I
interferon transcriptional signature among circulating
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PBMC [28]. BO-112 is a nanoplexed form of Poly I:C
coupled to polyethylenimine (PEI) reminiscent of BO-
110, a previous format of the compound that was
found to in-vivo induce apoptosis in melanoma cells
as a result of intense autophagy [31, 32].
In this article, we studied the immunotherapeutic profile
of BO-112 following intratumoral delivery in experimental
models. Our observations include induction of immuno-
genic cell death in a small fraction of tumor cells and object-
ive immunotherapeutic activity dependent on Interferon-γ
(IFNγ) and type-I interferon. Finally, we show the involve-
ment of BATF-3-dependent conventional type-I dendritic
cells (cDC1) [33].
Materials and methods
Animals and cell lines
Animal studies were approved by the Ethics Committee
of Animal Experimentation (CEEA) of the CNB and of
the CIMA with compliance with national, institutional
and EU guidelines. Six- to eight-week-old female BALB/c
and C57Bl/6 were purchased from Envigo (www.envigo.
com). C57Bl/6 Batf3tm1Kmm/J (Batf3−/−) [33] and IFN-a/bRo/o
(IFNARKO) [34] were kindly provided, by Dr. Kenneth M.
Murphy, Washington University, St. Louis, MO and by
Matthew Albert (Institut Pasteur, Paris) respectively, and
were bred at CIMA in specific pathogen-free conditions.
Mice were housed in the Animal Facility of Centro
Nacional de Biotecnologia (CNB-CSIC, Madrid, Spain)
and Centro de Investigacion Medica Aplicada (CIMA,
Pamplona, Spain).
B16-F10 mouse melanoma cells and 4 T1 mouse
breast carcinoma were purchased from the ATCC, and
B16-OVA melanoma cells and MC38 colon carcinoma cells
were a kind gift from Dr. Lieping Chen (Yale University,
New Heaven, CT) and Dr. Karl E. Hellström (University of
Washington, Seattle, WA) respectively. Tumor cells were
cultured in RPMI 1640 (Gibco) containing 10% fetal bovine
serum (FBS, Sigma-Aldrich), 2mM glutamine (Gln, Gibco),
100U/ml penicillin and 100 μg/ml streptomycin (100U/ml),
and 50 μM 2-mercaptoethanol (Gibco). The B16-OVA cell
line was supplemented with 400 μg/mL Geneticin (Gibco).
Cell lines were routinely tested for mycoplasma contamin-
ation (MycoAlert Mycoplasma Detection Kit, Lonza).
UMBY and ICNI human melanoma were derived from
primary surgical samples of metastatic lesions of patients
at the Department of Dermatology, University Hospital
Erlangen and grown in DMEM (Gibco) containing 10%
FBS, 4 mM Gln and 1% P/S. HT-29 and HCT 116 colon
cancer from the ATCC were cultured in RPMI, 2 mM
Gln, 10% FBS and 1% P/S. SK-BR-3 and BT-474 breast
cancer cell lines were a kind gift from Dr. López-Botet,
IMIM, Barcelona and were grown in DMEM/F12
(1:1) (Invitrogen), containing 2.5 mM Gln, 10% STF
and 1% P/S.
BO-112
BO-112 was developed and provided by Bioncotech
Therapeutics (Madrid, Spain). All experiments were per-
formed with the same batch.
In vitro experiments
The in vitro cytotoxicity of BO-112 in mouse and
human cell lines was continuously assessed by measur-
ing electric impedance in an xCELLigence machine
(ACEA). Tumor cells (1.5-2 × 105) were seeded on spe-
cific 8-well plates to measure electric impedance. After
4-5 h, BO-112 or Poly I:C (Sigma) was added to culture
media at identical concentrations in a final volume of
200 μL per well. PEI (Polyplus-transfection®) was added
to culture media at the same concentrations as it is
present in BO-112 formulation. Electric impedance was
measured every five minutes for 48 h. In vitro BO-112
cytotoxicity was also assessed by the CellTiter AQueous
One Solution Cell Proliferation Assay (MTS, Promega).
Briefly, tumor cells (5 × 103 cells/well; 96 flat-well plates,
8 replicates per condition) were cultured for 48 h, alone
or with BO-112 (0.25, 0.5 and 1 μg/mL) and absorbance
(OD 492 nm) measured in an ELISA plate reader. Three
independent MTS assays were performed. Cell viability
is referred to untreated cells (100%).
For RNA expression analyses, B16-OVA cell lines were
cultured 24 h with BO-112 at 0.5 μg/mL or in the pres-
ence of equivalent volumes of BO-112 vehicle.
HMGB1 detection in culture supernatants was per-
formed with HMGB1 ELISA detection kit following the
manufacturer’s instructions (IBL International ST51011).
In vivo experiments
B16-F10 and B16-OVA melanoma, MC38 colon carcin-
oma or 4 T1 breast carcinoma cells were injected sub-
cutaneously (5 × 105–106) into the right flank of 8- to
10-week-old female C57BL/6 or BALB/c (6–11 mice/
group) on day 0. Tumors were measured twice per week
with calipers and the volume calculated (length x width2/2).
When tumors reached a volume of 80–100mm3 (day 0)
mice were randomized into different groups of treatment
according to the experiment. Poly I:C or BO-112 formula-
tion (2.5mg/Kg, 100 μl), was administered by intratumoral
injection twice per week for three weeks (six doses in total).
The control group received intratumoral injections of 5%
glucose (BO-112 vehicle, identical volume) or PEI (identical
amount per dose as present in each dose of BO-112).
Survival was monitored daily, and tumors were measured
twice per week until the animals died or the tumor volume
reached the maximum allowed size.
To evaluate the systemic antitumor effects, 5 × 105
(injected/treated tumor) and 1.5 × 105 (contralateral
tumor) B16-OVA cells were injected into each flank re-
spectively. For evaluation of cDC1 in BO-112-meditated
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antitumor response, identical experiments were performed
in Batf3−/− mice (in parallel with WT mouse groups). For
evaluation of intratumoral BO-112 in combination with
systemic immunostimulatory monoclonal antibodies, mice
were intratumorally injected with BO-112 or vehicle. The
intratumoral treatment schedule was the same as that
described for single tumor models. Starting at the second
BO-112 administration, mice received concomitant intra-
peritoneal administration (150 μg/dose) of either InVivo-
Plus anti-PD-L1 (10F.9G2), InVivo anti-CD137 (3H3) or
InVivoMAb rat IgG from BioXCell.
For flow cytometry, IHC and RNA extraction experi-
ments, mice received two intratumoral administrations
and were euthanized 48 h post-second dose.
Flow cytometry
Fresh tumors were excised from mice, weighed and
mechanically dissected and enzymatically digested for
15–30min at 37 °C with appropriate medium: DMEM
F-12 (Gibco), 1 mg/mL Collagenase 1A (Roche), 2.5 U/mL
Dispase (Roche), 20 U/mL DNAse-I (Roche), 20mM
HEPES (Lonza) and antibiotics. The enzymatic reaction
was stopped with 5% FBS in phosphate-buffered saline
(PBS). After hypotonic lysis, cell aggregates were removed
by filtering the cell suspension with a 70-μm cell strainer
(BD Falcon, BD Bioscience) and counted. Lymph nodes
were excised from mice and mechanically disrupted and
passed through a 70-μm cell strainer. Perfect count micro-
spheres (Cytognos) were used as an internal standard ac-
cording to the manufacturer’s instructions to calculate
absolute cell counts in cell suspensions.
Single cell suspensions from tumors and lymph nodes
were previously treated with FcR-Block (anti-CD16/32
clone 2.4G2; BD Biosciences Pharmingen) and were then
surface stained at 4 °C with fluorochrome-labeled antibody
cocktails defined for each staining. Tetramer staining was
performed according to the manufacturer’s protocol. Flow
cytometry antibodies, tetramers, cell death stainings and
isotype controls are listed in Additional file 1. Table S1.
For intracellular FOXP3 staining, cells were fixed and
permeabilized using the True-Nuclear™ Transcription
Factor Buffer Set (Biolegend).
Samples were acquired in a Gallios Cytometer (Beckman
Coulter), a FACSCanto II (BD Biosciences) and a Cyto-
FLEX Flow cytometer (BD Biosciences). Kaluza Flow Ana-
lysis Software (Beckman Coulter) and FlowJo (Treestar)
software were used for data analysis.
Depletion experiments
100–300 μg/dose of anti-CD4 (GK1.5), anti-CD8 (2.43),
anti-NK1.1 (PK136), anti-Gr1 (RB6-8C5) mAbs or Rat
IgG2b (LTF-2) from BioXCell, were injected one day be-
fore therapy, concurrently with the first intratumoral in-
jection and at days 3, 7, and 10 after the beginning of
therapy. Cell depletion was validated in blood samples
by flow cytometry analysis, showing a specific reduction
of more than 95% of each respective cell subset. Gr1 de-
pletion was confirmed in the tumor microenvironment
on day 7 (the day of the first BO-112 injection). For
IFNγ neutralization, mice were treated with 250 μg of
anti-IFNγ (XMG1.2) or rat IgG the day prior to each
BO-112 treatment. Then, mice were injected weekly
with for depletion maintenance (100 μg/dose).
Tissue histology and immunostaining
Formaldehyde-fixed and paraffin-embedded tissue sec-
tions (3 μm thick) were cut, dewaxed and hydrated. Heat
induced antigen retrieval was applied for 30 min at 95 °C
in 0,01M Tris-1 mM EDTA buffer (pH = 9) in a Pascal
pressure chamber (S2800, Dako). Sections were incu-
bated overnight at 4 °C with anti-CD4 (1:1000; Abcam,
ab183685) or anti-CD8 (1:300; Cell Signaling, 98,941)
Visualisation was performed using MACH 2 rabbit
AP-polymer (Biocare Medical, RALP525) with StayRed
(Abcam, ab103741) as chromogen according to the man-
ufacturer’s instructions.
RNA extraction
Total RNA was isolated in two steps using TRIzol (Life
technologies) and Rneasy Mini-Kit (Quiagen) purification,
following the manufacturer’s RNA cleanup protocol.
The assessment of RNA integrity was performed with
the Agilent 2100 bioanalyzer (Agilent Technologies)
and high-quality RNA was hybridized to Affymetrix
Clariom S Mouse Affymetrix microarrays following the
manufacturer’s protocol.
Gene expression analysis
The transcriptome experiment with Clariom S Mouse
Affymetrix microarrays was normalized using the Robust
Multichip Average (RMA) algorithm [35]. After quality
assessment, a filtering process was performed to eliminate
low expression probe sets. Applying the criterion of an ex-
pression value greater than 4 in at least 3 samples of one
of the experimental conditions (BO-112 or control sam-
ples), 21,731 probe sets were selected for statistical ana-
lysis in the in vivo experiment. Regarding the differential
expression analysis upon BO-112 incubation of B16-OVA
in vitro, 18,412 probe sets were selected for statistical ana-
lysis after applying the criterion of an expression value
greater than 4 in at least 2 samples of one of the experi-
mental conditions (BO-112 or control samples).
Linear Models for Microarray Data (LIMMA) [36] was
used to identify the probe sets that showed significantly
differential expression between experimental conditions.
Genes were selected as significant using a B-statistic
cut-off (B > 0). R and Bioconductor were used for pre-
processing and statistical analysis [37].
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The functional enrichment analysis was performed
using Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com), whose database includes manually
curated and fully traceable data derived from literature
sources. In addition, enrichment analyses of some gene sets
of interest extracted from different publications [38, 39]
were performed using the hypergeometric distribution in R
[37]. Microarray expression data can be downloaded from
Gene Expression Omnibus (GEO) under the Series acces-
sion number GSE116078.
Statistical analysis
Statistical analyses were performed using Prism software
(GraphPad Software, Inc.). A two-tailed Student’s t-test
or Mann–Whitney tests were used to analyze statistical
differences between groups. The Mantel-Cox test was
used for survival analysis. For tumor growth data ana-
lyses, mean volumes of tumors over time were fitted
using the formula y = A x e (t-t0) / (1 + e(t-t0)/B), where
t represents time, A the maximum size reached by the
tumor and B its growth rate. Treatments were compared
using the extra sum-of-squares F test. Values of p < 0.05
(*), p < 0.01 (**) and p < 0.001 (***) were considered
significant.
Results
Intratumoral BO-112 controls transplanted syngeneic
tumors and induces cell death in a fraction of malignant
cells
BO-112 is a GMP-grade pharmaceutical composition of
nanoplexed Poly I:C (300–5000 mer) coupled to poly-
ethylenimine characterized by their monomodal diameter
distribution (at least 90% of particles mono-modal diameter
distribution bellow 300 nm) and z-average diameter (less or
equal 150 nm) (PCTEP2016078078, Additional file 2:
Figure S1). Previous forms of Poly IC-PEI nanocomplexes
termed BO-110 have been intravenously delivered in mouse
models giving rise to therapeutic effects against subcutane-
ous transplanted melanomas in a fashion related to its
ability to induce tumor cell apoptosis in the context
of intense autophagy elicited via MDA5 stimulation in
malignant cells [31, 32].
In keeping with those findings, Fig. 1a shows that
BO-112 induces death in a dose-dependent manner in
cultured cell lines able to engraft in syngeneic mice
representing melanoma (B16-F10, B16-OVA), colon can-
cer (MC38) and triple negative breast cancer (4 T1). Tu-
mors derived from such cell lines are described as poorly
immunogenic and difficult to treat with immunotherapy
[40]. BO-112-induced cytotoxicity was also observed in a
panel of human cell lines (Additional file 3: Figure S2A),
including melanoma, colon cancer and breast cancer. Of
particular importance, identical concentrations of Poly I:C
were not cytotoxic in either mouse or human tumor cell
lines (Fig. 1a and Additional file 3: Figure S2A). These re-
sults were further confirmed by measuring cytotoxicity in
MTS assays in mouse and human cell lines (Additional
file 3: Figure S2B).
To study the effects of intratumoral injection in subcuta-
neous malignant nodules derived from these tumor-cell
lines upon engraftment in syngeneic mice, BO-112, Poly
I:C or vehicle were repeatedly delivered intratumorally
when tumors reached a volume of 80–100mm3 (Fig. 1b
and c). Figure 1b shows the very clear therapeutic effects of
BO-112 at halting and delaying B16-F10 tumor progression,
that were not seen in the mice randomized to receive injec-
tion of either Poly I:C or vehicle. Representative photo-
graphs showing B16-OVA tumors at day 15 are shown in
Fig. 1b (inset). BO-112 antitumor therapeutic effects were
also observed in MC38- and 4 T1-tumor bearing mice
upon a similar repeated intratumoral treatment regimen
with BO-112 (Fig. 1c).
Next, we examined whether BO-112 could induce local
tumor cell death in an immunogenic fashion [41, 42]. In
B16-OVA cultures, tumor cell death was abundant 24 and
48 h after exposure to BO-112 in the form of apoptosis
characterized by Annexin V binding and loss of plasma
membrane integrity (7AAD staining), as shown in Fig. 2a.
This increase in apoptotic cell subsets was also observed
in BO-112-treated human cell lines (Additional file 3:
Figure S2C). Interestingly, dying or dead cells showed mo-
lecular features associated with immunogenic cell death
[42] including calreticulin (CRT) exposure on the outer
leaf of the plasma membrane, and HMGB1 release to
the culture supernatant and CD95 surface expression
(Fig. 2b). Such cells also showed enhanced surface ex-
pression of MHC class I. Importantly, identical con-
centrations of Poly I:C added to the culture media
failed to induce these hallmarks of immunogenic cell
death (Fig. 2b) in tumor cells.
When treating subcutaneous tumors derived from
B16-OVA (Fig. 2c), a fraction of apoptotic cells could be
observed five days after the onset of intratumoral treat-
ment. Interestingly, in CD45- cells obtained from the
tumor nodules there was an increased surface expression
of MHC-I, CRT and CD95 (Fig. 2c), suggesting features
of immunogenic cell death in vivo. Of note, PEI itself
(without Poly I:C) was not cytoxic in culture and did not
affect progression of B16-OVA melanomas following re-
peated intratumoral administration in the same quan-
tities as those present in BO112 (Additional file 4:
Figure S3 A-C).
Intratumoral administration is required for antitumor
activity as opposed to subcutaneous delivery
Since direct intratumoral injection of BO-112 therapeutic-
ally controlled tumor progression, we tested whether simi-
lar results could be achieved by subcutaneous delivery
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elsewhere in the mouse. Such experiments compar-
ing intratumoral versus subcutaneous delivery at the
same doses were performed in MC38 and B16-OVA
tumor-bearing mice (Additional file 5: Figure S4). As
shown in Additional file 5: Figure S4, while intratumoral
delivery controlled tumor progression, this was not the
case for subcutaneous administrations which failed to
control tumor progression. Accordingly, intratumoral re-
lease is more efficacious than subcutaneous release under
identical experimental conditions.
Fig. 1 Local injection of BO-112 exerts antitumor effects. a. Cell viability (in terms of electric impedance) of cultured tumor cell lines was
measured in xCELLigence plates over time in the presence of different concentrations of BO-112 or Poly I:C as indicated, to study effects on cell
viability. b. Tumor volume follow-up of in vivo engrafted syngeneic B16F10 tumors treated intratumorally with control vehicle, Poly I:C or BO-112
as indicated in the diagram. Representative photographs of mice treated with BO-112, Poly I:C or control vehicle are included as an inset. c.
Individual follow-up of tumor volume means ± SD (in graphs on the right) of MC38 and 4 T1-bearing mice treated with BO-112 or control vehicle
as indicated. Experiments are representative of two similarly performed. ***P < 0.001
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Intratumoral BO-112 increases CD8+ tumor infiltrating
lymphocytes and CD8/Treg ratios
Intratumoral BO-112 therapeutic effects could be the re-
sult of direct tumor cell death or the result of enhanced
antitumor immune responses or a combination of both
factors. To start addressing this question, we studied the
composition of the lymphoid infiltrates following BO-112
intratumoral delivery in B16-OVA-derived tumors (Fig. 3a
and Additional file 6: Figure S5). Interestingly, we ob-
served changes in the leukocyte tumor microenvironment
Fig. 2 BO-112 induces immunogenic cell death. The characterization of tumor cell death (apoptosis, necrosis, immunogenic cell death) induced
by BO-112 was investigated in vitro and in vivo. a. and b. B16-OVA cells (105 cells/well) were cultured alone or with BO-112 or Poly IC (0.25, 0.5
and 1 μg/ml), for 24 and 48 h. a. Apoptosis and necrosis were analyzed by flow cytometry upon staining with Annexin V and 7AAD. b.
Immunogenic cell death (ICD) hallmarks were analyzed by flow cytometry studying cell surface expression of MHC-I, CD95 and Calreticulin and
by measuring HMGB1 release. c. B16-OVA tumor bearing mice were intratumorally treated with BO-112 or vehicle (n = 5 per group). The diagram
shows the schedule of the experiment. Graphs show that intratumoral administration of BO-112 leads to a significant increase in tumor cell
apoptosis and necrosis (left) and also promotes the expression of ICD-associated markers on tumor cells. *P < 0.05, **P < 0.01***P < 0.001
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Fig. 3 BO-112 intratumoral injection enhances T lymphocyte infiltrates. a. Schematic representation of the experiments to surgically harvest
tumors following treatment to generate cell suspensions that were analyzed by flow cytometry. b. CD8/CD4 and CD8/Treg ratios in cell
suspensions. c. Percentage of CD8+, CD4+ and CD25+FOXP3+ over total intratumoral CD45+ leukocytes and absolute numbers per gram of tumor
tissue. d. Representative microphotographs of CD4 and CD8 immunohistochemistry analyses of sections derived from B16-OVA tumors treated as
indicated. Scale bar of the main microphotograph: 100 μm. Scale bar of the inset: 60 μm. Positive cells are stained in magenta.
*P < 0.05, **P < 0.01***P < 0.001
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in favor of CD8+ cells in proportion to CD4+ T cells and
regulatory T cells (Tregs) (Fig. 3b). In fact, higher numbers
of CD8+ cells could be observed per gram of tumor tissue,
whereas FOXP3−CD4+ and FOXP3+CD25+CD4+ Tregs
cells decreased (Fig. 3c). These infiltrates were evenly dis-
tributed in the tumors as representative microphotographs
in Fig. 3d show.
Efficacy of intratumoral BO-112 given unilaterally to
bilaterally tumor-bearing mice in conjunction with
systemic anti-CD137 and anti-PD-L1 monoclonal
antibodies
The intratumoral route in all detectable tumors might
be possible in oligometastatic patients, but impossible in
most advanced cancer patients. Furthermore, microscopic
metastatic disease will not be amenable to intratumoral
treatment. Therefore, we performed experiments in
B16-OVA tumor-bearing mice in which only one of the
subcutaneously engrafted tumors was treated (Fig. 4a).
These mice were intraperitoneally co-treated with control
antibody or immunomodulatory mAbs agonistic for
CD137 [43] or antagonistic for PD-L1 [44]. As seen in
Fig. 4b and c, BO-112 exerted clear local control of the
disease as compared to vehicle. Such local control was en-
hanced to some extent by both anti-CD137 and
anti-PD-L1 mAbs, which did not show any meaningful
therapeutic activity by themselves, as shown in their com-
bination with intratumoral control vehicle.
When examining distant tumors (non-injected with
BO-112), some degree of tumor-growth control by
BO-112 was observed with death of mice being postponed
for approximately 1–2 weeks (Fig. 4b and c). Furthermore,
when systemic anti-CD137 mAb was used such distant
tumor control was further enhanced, although not signifi-
cantly in the case of anti-PD-L1-treated mice. In this
difficult-to-treat melanoma model, our data argue in favor
of systemic antitumor activity that might be potentiated
by combinations with other immuno-oncology agents.
In B16-OVA tumors intratumorally treated with
BO-112, we were able to observe increases in the ex-
pression levels of the targets for immunomodulatory
mAbs on tumor-infiltrating T cells 48 h following the
second BO-112 administration. PD-1 expression mark-
edly rose on CD8+ T cells, while CD137 expression was
also increased, albeit to a lesser extent (Additional file 7:
Figure S6A). Curiously, CD137 was clearly upregulated
on NK lymphocytes retrieved from treated tumors.
Moreover, PD-L1 levels of surface expression increased
on T cells (CD8+ and CD4+), as well as on NK cells
(Additional file 7: Figure S6A). Therefore BO-112 intra-
tumoral treatment at least locally upregulates the targets
for the mAbs used in the immunotherapy combinations,
including CD8+ T cells that co-expressed both PD-1 and
CD137 on their surface (Additional file 7: Figure S6B).
In MC38-derived tumors, BO-112 intratumor injections
clearly induced an enrichment of PD1+, CD137+ and double
positive CD137+PD-1+ among CD8+ T cells, although total
CD8+ were not augmented (Additional file 8: Figure S7A
and B). In line with these findings, in B16-OVA-derived
tumors, FOXP3−CD4+ and FOXP3+CD25+CD4+ cells per
gram of tumor tissue were reduced following BO-112 treat-
ment (Additional file 8: Figure S7C).
Intratumoral BO-112 enlarges tumor-draining lymph
nodes containing abundant CD8+ T cells
Intratumoral release not only reaches the tumor micro-
environment itself, but also drains to lymph nodes. In our
hands, two intratumoral injections of BO-112 at thera-
peutic doses (Fig. 5a) in B16-OVA-tumor bearing mice re-
sulted in prominent draining lymph node enlargements
(Fig. 5b), as a result of an enhanced contents of CD45+
leukocytes. Again, CD8+/ CD4+ and CD8+/Treg ratios
were markedly increased by treatment in most tumors,
while non-draining lymph nodes remained normal (data
not shown). Of interest, while numbers of effector CD8+
and CD4+ T cells rose, Tregs remained stable (Fig. 5c).
Antitumor activity of intratumoral BO-112 requires IFNγ
and correlates with increases in tumor-reactive CD8+ T cells
Results from tumor infiltrates suggested that an important
component in the therapy was mediated by the immune
system. To determine which cell subsets were involved in
the BO-112 tumor growth delay, depletion experiments
were performed in MC38 and B16-OVA tumors. Antitumor
effects on MC38-derived tumors completely disappeared
when CD8β
+ T cells were depleted in vivo, while CD4+ T
cells were dispensable (Additional file 9: Figure S8A and B).
By contrast, single CD8 subset depletion induced only a
partial loss of efficacy and single CD4+ and NK+ subset
depletion had not impact in BO-112-mediated antitumor
response in B16-OVA mouse models. (Additional file 10:
Figure S9 A and B). Interestingly, triple depletion of
NK1.1+, CD4+ and CD8+ had a major impact on
BO-112 therapeutic effects (Additional file 10: Figure S9 B),
although such loss of efficacy was not complete, indicating
that other mechanisms are involved in BO-112-induced
antitumor response. In addition, myeloid Gr-1+ cells
were dispensable (Additional file 10: Figure S11 A and B).
Depletions were verified in peripheral blood by flow cytom-
etry (Additional file 9: Figure S8C and Additional file 10:
Figure S9 C and D), and Gr-1 depletion was additionally
verified in both blood and tumor (Additional file 11:
Figure S10 C and D).
The immunotherapeutic effects mediated by CD8+ T
cells are usually dependent on IFNγ and the critical con-
tribution of this cytokine to intratumoral BO-112 effi-
cacy was revealed in BO-112-treated B16-F10 tumors
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when IFNγ was systemically neutralized with a specific
mAb (Additional file 11: Figure S10E).
Various tumor specificities of CD8+ T lymphocytes in
TDLN and in the tumor microenvironment can be
monitored with H-2kb tetramers refolded with well-
studied immunodominant CTL epitopes such as Ovalbu-
min (OVA) and TRP2 in B16-OVA, and gp70 in the
MC38 model. In this regard, injections of BO-112 into
Fig. 4 Immunotherapeutic effects of combinations of intratumoral BO-112 with systemic anti-CD137 or anti-PD-L1 monoclonal antibodies. a.
Schematic representation of experiments in mice bearing two B16-OVA-derived tumors engrafted on opposite flanks and intratumorally treated
with BO-112 only in the right lesion and with intraperitoneal administrations of immunomodulatory monoclonal antibodies as indicated. b.
Tumor volume follow-up of the injected and distant tumors in the different groups of treatment. c. Mean ± SD summary indicating statistical
significance of the listed comparisons. *P < 0.05, **P < 0.01***P < 0.001
Aznar et al. Journal for ImmunoTherapy of Cancer           (2019) 7:116 Page 9 of 16
B16-OVA tumors resulted in increased contents CD8+ T
cells recognizing TRP-2 and OVA as a surrogate tumor
antigen in tumors (Fig. 5d) and in TDLN (Fig. 5e).
In line with these findings in B16-OVA models, a
remarkable increase of gp70-specific intratumor CD8+
T cells was found in MC38-tumor bearing mice
treated intratumorally with BO-112 (Additional file 12
Figure 11).
Intratumoral BO-112 induces an IFNα/β-related
transcriptomic profile and type I interferon as well as
cDC1 dendritic cells are required for antitumor effects
Previous reports have linked Poly I:C delivery to IFNα/β
release [45, 46]. We genome-wide analyzed the mRNAs
expressed in B16-OVA tumors 48 h following the second
intratumoral BO-112 administration in comparison with
control Vehicle (Fig. 6a and Additional file 13: Figure S12)
Fig. 5 BO-112 intratumoral injection induces tumor-draining lymph node enlargement and increases CD8 T cells recognizing specific antigens. a.
Scheme of experimental treatment showing representative size of TDLN and their total leukocyte content in the graph comparing mice treated
intratumorally with BO-112 or control vehicle. b and c.: Analysis by flow cytometry of individual TDLN cell suspensions. b. CD8 to CD4 ratios and
CD8/Treg ratios. c. represents the absolute number of the indicated T-cell subsets in TDLNs. d. Class I MHC tetramer stainings to identify T cells
recognizing OVA-specific epitope and TRP-2 among CD8 T cells per gram of malignant tissue in mice bearing B16-OVA tumors. e Class I MHC
tetramer stainings to identify the numbers OVA- and TRP2-specific CD8+ T cells in TDLN. Absolute numbers are provided for antigen-specific CD8
T cells. *P < 0.05, **P < 0.01***P < 0.001
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and in B16-OVA cell cultures following 24 h incubation
with BO-112 of Vehicle (Additional file 14: Figure S13).
As expected, a very clear differential gene expression
profile was found upon intratumoral BO-112 adminis-
tration, involving key immune-response genes whose
expression rose in a clear-cut pattern, as shown in the
hierarchical clustering of Fig. 6b and extended data in
Additional file 15: Table S2. The differentially expressed
gene set was significantly enriched in immune-response
gene signatures involved in Interferon signaling and retin-
oic acid-mediated apoptosis (Fig. 7c and Additional file 16:
Table S3). The BO-112-induced transcriptional profile was
also enriched in previously reported gene signatures that
suggest infiltration by activated immune cells and cytolytic
activity [38, 39] (Fig. 6d). This gene expression pattern is
comparable to that induced by poly I:C, since it best fits in
Ingenuity pathway analysis (IPA) what has been described
for cell exposure to Poly I:C, as expected from stimulation
of TLR3 and cytosolic pattern recognition receptors
(PRRs) (Additional file 17: Table S4).
Key genes involved in IRF activation by cytosolic PRRs,
IFN signaling, retinoic acid-mediated apoptosis were among
Fig. 6 Intratumoral BO-112 induces potent type-I IFN-related transcriptomic changes. a. Mice bearing B16-OVA tumors were treated with
intratumoral BO-112 or vehicle (n = 5 per group) and total RNA was extracted as indicated to be genome-wide analyzed by gene expression
microarrays. Differentially expressed transcripts were obtained by Linear Models for Microarray Data (LIMMA) analysis (b). Hierarchical clustering of
differentially expressed genes between both experimental conditions. Most relevant genes for immune functions are indicated as upregulated by
BO-112. c. Top canonical pathways upregulated by BO-112 treatment as defined by Ingenuity Pathway Analysis of the differentially expressed
transcripts. d. Heat map representing enrichment analyses of key previously described signatures for IFNα and IFNγ stimulation, for tumor cell
infiltration and activation of TILs as well as T-cell effector-related transcripts
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the 254 differentially expressed genes shared between in
vitro and in vivo experiments (Additional file 14: Figure
S13), while other key immunoregulatory genes were upregu-
lated by BO-112 in B16-OVA cell cultures (Additional file 14:
Figure S13B and Additional file 18: Table S5).
All these effects on the transcriptomic profiles
speak of an excellent mimicry of viral infection in the
BO-112-injected tumor microenvironment conducive
to the enhancement of anti-tumor cytotoxic T-cell
responses.
As suggested by the observed induced expression of
IFN-I, IFNARKO mice bearing B16-OVA tumors were
found not to respond to intratumor BO-112, thereby
providing evidence for the key role of IFNα/β signaling for
the antitumor response induced by BO-112 (Fig. 7a).
Tumor antigen crosspriming is known to be up-regulated
by type I IFN and TLR3 function. CD8 T-cell crossprim-
ing is critically mediated by so called conventional type-I
dendritic cells (cDC1) that are absent in BATF3−/− mice
[33]. Experiments of intratumoral treatment with BO-112
performed in BATF-3−/− mice bearing two B16-OVA tu-
mors (in which one was left uninjected) showed that this
cDC-1 subset is crucial for the therapeutic response to
local BO-112, since the progression delay mediated by in
situ delivery of BO-112 was completely lost when com-
pared to wild type mice (Fig. 7b).
Fig. 7 Antitumor response of intratumoral BO-112 is dependent on IFNα signaling and on Batf3-dependent Dendritic Cells. a. Tumor volume
follow-up of WT and IFNARKO mice bearing B16-OVA tumors that were treated with intratumoral BO-112 or vehicle (n = 6 per group) as indicated
in the diagram. Individual tumor volume and tumor volume means ± SD are shown. b. Tumor volume growth of WT or Batf3−/− (BATF3KO) mice
bearing two B16-OVA-derived tumors in which one was treated with BO-112 or vehicle (n = 6 per group) as indicated in the diagram. Tumor
volume means ± SD are shown in graphs on the right. *P < 0.05, **P < 0.01***P < 0.001
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Discussion
In this study we have explored BO-112, a nanoparticled
form of Poly I:C administered via the intratumoral route.
Intratumoral delivery of immunotherapy came to age with
the FDA approval of the HSV-1 vector T-vec for locally
advanced or metastatic melanoma [47]. However viral
vectors are immunogenic and often encode pathogenic
factors that downregulate cellular immunity. Viral-like
nanoparticles such as BO-112 have the theoretical advan-
tage of lacking immunogenicity, thus theoretically permit-
ting limitless dose repetition. Moreover, they do not need
the logistical and safety cautions that must be taken into
account with viruses or modified recombinant viruses. In
addition, a very strong dsRNA immunostimulatory profile
proceeds unchecked by any interference from counteract-
ing viral immunosuppressive proteins.
In our hands, BO-112 is therapeutically active when
used intratumorally, showing anti-tumoral efficacy in ex-
perimental settings in which intratumoral Poly I:C did
not. This offers advantages since doses can be kept far
from toxic thresholds, while achieving at least local anti-
tumor effects. Interestingly, similar subcutaneous dosing
of BO-112 shows no efficacy as compared to intratu-
moral release. Consistent with other forms of Poly I:C,
intratumoral BO-112 is safe in mice and achieves
marked tumor control of injected transplanted tumors
including poorly immunogenic variants.
Mechanistic studies dissecting the mode of action result
in the following model: first, BO-112 induces cell death in a
small fraction of tumor cells in the context of alarmins de-
noting stressful non-programmed cell death [42]. This may
result in tumor antigen release and crosspresentation by
professional antigen-presenting cells [48] including BATF-3
dependent c-DC1. At the same time, strong IFNα/β release
and other proinflammatory mediators act as a local adju-
vant in this context of in-situ vaccination [11, 49]. As a con-
sequence, a tumor-specific CD8 immune response is
mounted or augmented to the point of controlling tumor
progression, both in the locally injected lesion and to some
extent in distantly implanted tumor nodules. This is con-
sistent with increases of tumor-specific CD8 T cells in the
tumor microenvironment and TDLNs.
Mechanisms aside adaptive immunity are operational
in the treatment as seen upon simultaneous depletion of
T and NK lymphocytes. On the one hand there are
direct cytotoxic effects to tumor cells and on the other
there might be effects on the functionality of innate im-
mune cells other than NK lymphocytes.
Other TLR [1] and STING [50] agonists are being
developed for intratumoral injection in the clinic (for
instance, the following ongoing clinical trials registered
in clinicaltrial.gov: NCT02927964; NCT02423863;
NCT02501473; NCT03172936). However, the induction
of immunogenic cell death to a certain level could be an
important advantage in the case of BO-112. It remains
to be seen which, or which combination, of agonists to
PRRs behaves as the most beneficial when injected
intratumorally.
In the era of checkpoint inhibitors, combinations of
local agents and systemic immunomodulatory mAbs make
much sense [51]. In the case of intratumoral BO-112, we
observe some additive effects with anti-PD-L1 and
anti-CD137 mAbs, that were not truly synergistic. In this
regard, clinical reports on results of the anti-PD-1 mAb
combinations with other TLR agonists such as G100, CpG
oligonucleotides and STING agonists given locally are
eagerly expected. This is also the case of intratumoral
oncolytic virus T-vec that in combination with pembroli-
zumab has shown remarkable responses in metastatic
melanoma patients [52], being pending of the results of
the randomized clinical trial MASTERKEY 265 in com-
bination with pembrolizumab versus pembrolizumab
alone (NCT02263508). In the case of BO-112, the expres-
sion of CD137 and PD-1/PD-L1 was increased on tumor
infiltrating T and NK cells, a fact that hinted at the poten-
tial combinability of the dual local and systemic approach.
All things considered, we have observed that intratu-
moral BO-112 is active in local cancer immunotherapy. It
remains to be studied what would be the best combin-
ation regimen, but for the time being BO-112 is com-
bined in the clinic with anti-PD-1 mAbs, since our
results have been conductive to an ongoing clinical trial
(NCT02828098) which is testing the safety and clinical
activity of intratumoral BO-112 either as a single agent or
in combination with nivolumab or pembrolizumab check-
point inhibitors. The transcriptomic gene-expression pro-
file induced by BO-112 in engrafted mouse tumors offers
potential for pharmacodynamics biomarkers and, as a
consequence, RNA expression assessments are being
carried out in pre- and post-treatment biopsies of injected
tumors taken from patients on trial.
Conclusions
Nanoplexed Poly I:C (BO-112) when locally injected in-
duces immunogenic cell death in a fraction of tumor cells
and exerts potent antitumor activity via strong induction
of type I interferon and CD8 T-cell infiltrates in the tumor
microenvironment. As a result of these findings intratu-
moral BO-112 is undergoing phase I/II clinical trials.
Additional files
Additional file 1: Table S1. Flow cytometry mAbs and other staining
dyes employed for multiparametric flow cytometry analyses. (XLSX 12 kb)
Additional file 2: Figure S1. A representative BO-112 intensity size
distribution is presented, that was determined by Dynamic Light Scattering
(DLS), a non-invasive technique for measuring the size of particles in suspension.
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Above of the DLS graph there is a cartoon representing the postulated
structure of a BO-112 nanocomplex. (TIF 513 kb)
Additional file 3: Figure S2. BO-112 cytotoxic effects on human tumor
cell lines. A. Cell viability experiments as in Fig. 1a showing the effects of
various doses of BO-112 or Poly I:C on human tumor cell lines representing
melanoma, colon cancer and breast cancer. B. Cell viability of B16-OVA,
MC38, HCT 116 and HT-29 tumor cell lines upon incubation with increasing
amounts of BO-112 for 24 and 48 h. Cell viability was assessed by MTS assay.
% Viability is referred to untreated cells. C. Early and late apoptosis assessment
induced by BO-112 in two representative human tumor cell lines measured
by flow cytometry as in Fig. 2a. (TIF 1168 kb)
Additional file 4: Figure S3. Intratumor delivery of polyethylenimine is
unable to induce therapeutic effects. A. xCELLigence experiments as in Fig. 1a
showing B16-OVA cell viability upon in vitro incubation with BO-112 or PEI in
equivalent amounts as present in each BO-112 dose. B. Timeline showing the
treatment schedule of intratumoral administrations of BO-112 or PEI in B16-
OVA models. Mice were injected subcutaneously with B16-OVA at day 0
(5 × 105 cells) in the right flank. When tumor size reached 80–100mm3,
animals were treated with PEI or BO-112 by injection into the tumor nodules
(i.t). Plots show individual volume (length x width2/2) for control (vehicle) and
PEI and BO-112 treated mice. ***P< 0.001. (TIF 4613 kb)
Additional file 5: Figure S4. BO-112 therapeutic effects require
intratumoral administration. A. Timeline showing the schedule of
experimental treatment. All mice were injected subcutaneously with B16-
OVA or MC38 murine colon carcinoma cells at day 0 (5 × 105 cells) in the
right flank. After mice randomization (when tumor size reached 80–100
mm3), animals were treated with BO-112 by injection into the tumor
nodules (i.t) or by subcutaneous injection in the left flank (s.c). Plots show
individual volume (length x width2/2) for control (vehicle) and BO-112
treated mice, following i.t and s.c routes of drug administration as
indicated. ***P < 0.001 (TIF 5096 kb)
Additional file 6: Figure S5. Gating strategy for flow cytometry
analyses to study tumor infiltration in in vivo experiments. Flow
cytometry plots of a representative sample showing the gating strategy
for TIL analysis. (TIF 1065 kb)
Additional file 7: Figure S6. Expression of CD137, PD-1 and PD-L1 on
infiltrating lymphocytes from BO-112-treated B16-OVA tumors. A. Flow
cytometry analysis of the intensity of expression of surface PD-1, CD137
and PD-L1 on gated CD4+, CD8+ and NK lymphocytes comparing tumors
treated with BO-112 or vehicle. B. Percentage of CD8+ cells coexpressing
PD-1 and CD137 and their density per gram of tumor as analyzed following
intratumoral treatment with BO-112 or control vehicle. **P < 0.01***P < 0.001
(TIF 1114 kb)
Additional file 8: Figure S7. BO-112 intratumoral injection enhances T
lymphocyte infiltrates of MC38 tumors. A. Schematic representation of
the experiments to generate cell suspensions of MC38 tumors that were
analyzed by flow cytometry. B. Flow cytometry frequencies of PD-1+,
CD137+ and PD-1+CD137+ double positive CD8+ in the CD8+ T cell
population infiltrating MC38 tumors after two intratumoral injections of
BO-112, and absolute numbers of CD8+ T cells per gram of tumor. C.
Absolute number per gram of CD4 and CD25 + CD4+ Tregs per gram of
tumor. *P < 0.05**P < 0.01 (TIF 3622 kb)
Additional file 9: Figure S8. CD8 depletion abrogate therapeutic
effects of BO-112 intratumoral delivery in MC38-tumor bearing mice. A.
Schematic representation of experiments on mice bearing MC38-derived
tumors for lymphocyte subset depletion. B. Individual follow-up upon
treatment with BO-112 or vehicle in mice depleted of CD8 or CD4 T cells
by specific monoclonal antibodies. C. CD4+ and CD8+ depletion validation
in peripheral blood of a representative group of animals was analyzed by
flow cytometry during the experimental procedure. **P < 0.01***P < 0.001.
(TIF 1913 kb)
Additional file 10: Figure S9. CD8, CD4 and NK depletion in B16-OVA
tumor-bearing mice treated with intratumoral BO-112. A. Schematic
representation of experiments on B16-OVA-tumor bearing mice that were
depleted from the indicated lymphocyte subsets. B. Individual tumor
volume follow-up in groups of mice intratumorally treated with with BO-
112 or vehicle and depleted from CD8+, CD4+ or NK1.1+ cells separately
or concomitantly. Lymphocyte cell subsets were selectively depleted by
specific monoclonal antibodies. The corresponding statistical comparisons
are summarized below the graphs. C. Representative dot plots of NK1.1+,
CD4+ and CD8+ lymphocyte depletions as assessed in peripheral blood
analyzed by flow cytometry during the experimental procedure. In D
levels of depletion achieved in individual mice are shown. *P < 0.05 **P <
0.01 ***P < 0.001. (TIF 2355 kb)
Additional file 11: Figure S10. Gr-1 depletion and IFNγ neutralization
in tumor-bearing mice treated with intratumoral BO-112. A. Schematic
representation of experiments on B16-OVA-tumor bearing mice that were
treated for Gr-1 depletion. B. Tumor volume follow-up in mice depleted
of Gr-1 cells by a specific monoclonal antibody and intratumorally treated
with with BO-112 or vehicle. C. Gr-1 depletion validation in B16-OVA tu-
mors analyzed by flow cytometry on day 7 coinciding with the first intra-
tumoral injection of BO-112. D. Gr-1+ depletion validation in peripheral
blood performed as in C. E. Experiments in B16-F10 melanoma-bearing
mice treated with intratumoral BO-112 or vehicle recording individual
tumor sizes. When indicated, mice were given neutralizing anti-IFNγ mAb
or isotype control. **P < 0.01***P < 0.001. (TIF 2920 kb)
Additional file 12: Figure S11. Increases of tumor-specific CD8+ T cells
recognizing the gp70 tumor antigen following BO-112 injections into
MC38 tumors. A. Diagram showing treatment schedule for MHC-I pentamer
staining to identify gp70-specific CD8 T cells in mice bearing MC38 tumors.
Frequencies of antigen-specific CD8 T cells infiltrating tumors (B.) and TDLNs
(C.) are shown. *P < 0.05. (TIF 2584 kb)
Additional file 13: Figure S12. Volcano Plot highlighting top differentially
expressed genes (as per FC) in BO-112-treated B16-OVA tumors. RNA derived
from B16-OVA tumors treated with intratumoral BO-112 or vehicle as indicated
in Fig. 6 was analyzed by expression microarrays. Differentially expressed genes
with a│logFC│> 1 and p > 0.01 are considered differentially expressed in
BO-112-treated B16-OVA tumors. (TIF 581 kb)
Additional file 14: Figure S13. Key immunoregulatory genes
differentially expressed upon BO-112 intratumoral administration are also
induced in B16-OVA cultures incubated with BO112. The B16-OVA cell
line was incubated either with BO-112 or vehicle for 24 h and its RNA
was genome wide analyzed with gene-expression microarrays. A. Venn
diagram showing the differentially expressed genes that were shared
with both in vitro and in vivo procedures (top) and top 19 canonical
pathways in predicted by Ingenuity Pathway analysis (bottom). B.
Hierarchical clustering of differentially expressed genes in B16-OVA
after BO-112 incubation. (TIF 964 kb)
Additional file 15: Table S2. Differentially expressed genes obtained
upon BO-112 intratumoral administration. Mice bearing B16-OVA tumors were
treated with intratumoral BO-112 or vehicle as indicated in Fig. 6, and total
RNA was extracted and analyzed by expression microarrays. Genes were
selected as significant using a B-statistic cut-off (B > 0). (XLSX 195 kb)
Additional file 16: Table S3. Top canonical differentially regulated
pathways induced by BO-112 intratumoral administration. Pathways from
differentially expressed genes upon BO-112 intratumoral administration
(selected as significant using a B-statistic cut-off B > 0) were identified
by Ingenuity Pathway Analysis. (XLS 35 kb)
Additional file 17: Table S4. Top 30 Upstream Regulators predicted to
promote the differentially expression profile induced by BO-112 intratumoral
administration. Upstream Regulators from differentially expressed genes
upon BO-112 intratumoral administration (selected as significant using a
B > 0 cut-off) were identified by Ingenuity Pathway Analysis. (XLSX 17 kb)
Additional file 18: Table S5. Differentially expressed genes induced by
BO-112 in B16-OVA in vitro. B16-OVA cell line was incubated either with
BO-112 or vehicle for 24 h and its RNA was genome wide analyzed with
gene-expression microarrays. Genes were selected as significant using a
B > 0 cut-off. (XLSX 241 kb)
Abbreviations
cDC1: conventional type-I dendritic cells; GEO: Gene Expression Omnibus;
IFN-I: Type-I interferon; IFNγ: Interferon-γ; IPA: Ingenuity Pathway Analysis;
LIMMA: Linear Models for Microarray Data; PRRs: cytosolic pattern
recognition receptors; RMA: Robust Multichip Average algorithm;
TDLN: Tumor-draining lymph nodes
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